Objective: The aim of this study was to compare the distribution and immunoreactivity of cyclooxygenase (COX) 1 and COX-2 in normal uterus and breast after long-term hormone therapy in postmenopausal monkeys.
P rostaglandins are a group of autocrine and paracrine hormones that play an important role in many physiological processes. The cyclooxygenase (COX) enzymes are key factors in the production of eicosanoids from arachidonic acid. The formation of prostaglandins depends on an intermediate molecule, prostaglandin H 2 . The prostaglandin synthases, COX-1 and COX-2, catalyze the formation of prostaglandin H 2 from arachidonic acid and are therefore important steps in prostaglandin formation. COXs and prostaglandins have been linked to inflammation, cell proliferation, enhanced angiogenesis, and promotion of invasion and metastasis of cancers. 1, 2 COX-1 is generally considered to be constitutively expressed in most tissues, whereas COX-2 is inducible. 2 Recent evidence shows that COX-1 is involved not only in physiological but also in pathological processes, including tumorigenesis in tissues such as those in the breast, cervix, and endometrium. 3<5 COX-2 is induced by mitogens, cytokines, growth factors, endotoxins, oncogenes, and carcinogens. 1 Its involvement in rheumatic disease, inflammation, and tumorigenesis has been demonstrated. 1, 4 COX-2 is indicated as a tumor promoter and a regulator of cell proliferation. 6 The biosynthesis of COX-1 and/or COX-2 is also up-regulated in breast and endometrial cancers. 1, 4 Hormone therapy (HT) with estrogen and estrogen + progestogen has been associated with an increased risk of cancer in hormone-sensitive tissues like the uterus and breast. 7 Breast cancer is the most common malignancy in women. 8 The estrogen receptor > (ER->) is expressed in most breast cancers. Estrogen is known to be a mitogen in human breast epithelium, and that effect is mediated through ER->. 9 Tamoxifen (TAM) has antiestrogenic properties in breast tissue and is commonly used as adjuvant treatment for patients with ER-positive breast cancers and as a prevention strategy for women at high risk of developing this disease. 10 TAM is pharmacologically complex because it manifests agonistic or antagonistic activity in a tissue-specific manner. TAM acts as an estrogen antagonist with antiproliferative effects in the breast, decreasing the risk of both invasive and noninvasive breast cancer while having agonistic effects on the endometrium. 10, 11 Tibolone (TIB) is a tissue-selective synthetic steroid, representing an alternative to conventional HT for women in Europe and Asia. 12 We and others have shown that the effects of TIB on breast tissue are less pronounced than those of estrogen-based HT. 13<17 In addition, TIB does not induce hyperplasia or carcinoma in the endometrium. 18, 19 Previous studies on vascular endothelium have indicated the regulation of COXs by estrogen and/or progestogen. 20 Since the uterus and breast are hormone sensitive organs, and HT is widely used in clinical practice, it is of utmost interest to study hormone regulation of COX expression in these tissues.
Knowledge of the normal physiology of the human breast and uterus is limited because of the difficulty in accessing normal tissues. The cynomolgus macaque (Macaca fascicularis) is a nonhuman primate that has well-documented similarities to humans in terms of reproductive physiology and anatomy, mammary gland development, peripheral steroid hormone metabolism, and sex steroid receptor expression. 21 In general, experimental findings in macaques have been predictive of outcomes in human reproductive studies. The aim of the present investigation was to compare the expressions of COX-1 and COX-2 in the normal uterus and breast after long-term HT.
METHODS

Animals
Female adult cynomolgus macaques (M. fascicularis) were imported from Indonesia to the United States. They were housed in social groups of four to six monkeys each. All experimental procedures involving animals were approved by the institutional animal care and use committee and are compliant with relevant federal regulations. The Wake Forest University School of Medicine is fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care. Bilateral ovariectomy was performed 3 months before the initiation of hormone treatment. The compounds were administered in the diet at doses equivalent, on a caloric basis, to those given to women. 22 The daily doses were thus designed to correspond to 0.625 mg conjugated equine estrogens (CEE), 2.5 mg medroxyprogesterone acetate (MPA), 20 mg TAM, and 3 mg TIB.
Experiment 1
More detailed data on animal treatment can be found in Cline et al. 23 All the macaques were 4 to 6 years old when the study started. The ovariectomized animals were treated orally for 35 months with CEE, MPA, CEE + MPA, or TAM. Animals without hormone treatment served as controls (C).
We obtained uterine tissues from 25 animals (C, n = 5; CEE, n = 4; MPA, n = 5; CEE + MPA, n = 5; TAM, n = 6) and breast tissues from 75 animals (n = 15 in all groups).
Experiment 2
Additional data on the animals studied are presented elsewhere. 15, 24 The monkeys were 6 to 8 years old at entry into the study. The ovariectomized animals were treated orally for 2 years with CEE, CEE + MPA, or TIB. Animals without hormone treatment served as C. We obtained uterine tissues from 88 monkeys (C, n = 20; CEE, n = 20; CEE + MPA, n = 20; TIB, n = 28) and breast tissues from 60 animals (n = 15 in all groups).
Tissue collection
All monkeys were euthanized after the treatment period, and reproductive tissues were evaluated as part of a multisystem approach. Uterine and breast tissue samples were collected and fixed in 4% paraformaldehyde for 24 hours, transferred to 70% ethanol, and stored in 4-C. The tissues were trimmed to 3 mm in thickness before being embedded in paraffin and were then sectioned at 5 Km for immunostaining.
Immunohistochemistry
All sections were deparaffinized using Bio-Clear, rehydrated in graded ethanol, and subjected to microwave treatment for antigen retrieval in 0.01 M citrate buffer (pH 6.0). Nonspecific endogenous peroxidase activity was blocked by treatment with 3% hydrogen peroxide. Before incubation with the primary antibody, all tissue sections were exposed to 10% normal horse serum for 60 minutes at room temperature. Two polyclonal goat antihuman antibodies (Santa Cruz Biotechnology), diluted 1:100, were used for the detection of COX-1 (Sc-1752) and COX-2 (Sc-1745). The primary antibody was incubated for 1 hour at 37-C. The secondary antibody, biotinylated horse antigoat (BA-9500; Vector Laboratories Inc., Burlingame, CA), was incubated for 30 minutes at room temperature. Immunostaining was performed using the Vectastain Elite ABCkit (Vector Laboratories Inc.) and diaminobenzidine (DAKOcytomation, Carpenteria, CA) as chromogen. Negative controls were obtained by omitting the primary antibody and replacing it with the corresponding concentration of goat immunoglobulin G (Fig. 2Q, R) .
Manual scoring
The intensity and tissue distribution of COX-1 and COX-2 immunostained cells were manually and independently evaluated by two observers blinded to treatment using a semiquantitative manual scoring on a 4-point scale: (j), negative; (+), faint; (++), moderate; and (+++), strong immunostaining.
Statistics
Statistical calculations were performed using an analysis of variance on ranks (Kruskal-Wallis test), and significance was evaluated by the Dunn test. The significance level was set at P G 0.05.
RESULTS
Immunohistochemistry (IHC) showed that COX-1 and COX-2 proteins were present in the cytoplasm of cells in both the uterus and breast in treated and control animals. Representative images from IHC are shown in Figure 1 
Uterus
In experiment 1, MPA treatment increased stromal COX-1 immunoreactivity compared with TAM treatment (Fig. 3A ; Table 1 ), whereas in experiment 2, CEE treatment decreased stromal COX-1 immunoreactivity compared with no treatment (C) ( Fig. 3C ; Table 1 ). In the glandular epithelium (GE) in experiment 2, CEE treatment increased COX-1 compared with other treatments (Fig. 3D ; Table 1 ). Combined CEE + MPA treatment decreased COX-1 immunoreactivity Table 1 ). TAM treatment did not differ in COX-1 immunostaining compared with controls ( Fig. 3A, B ; Table 1 ). In GE in experiment 1, there was a tendency that the groups treated with estrogenic compounds only (CEE and TAM) showed increased immunostaining of COX-1 compared with groups treated with MPA and combined CEE + MPA (P = 0.071; Table 1 ), which is in agreement with the increase found after CEE treatment in GE of experiment 2, as mentioned previously. In experiment 2, TIB treatment did not affect the COX-1 immunoreactivity in any tissue type compared with controls, but the immuno-staining after TIB treatment was lower than the immunostaining after CEE treatment in GE and higher than that after combined CEE + MPA treatment in myometrium ( Fig. 3C , D, E; Table 1 ).
Neither the CEE-or TAM-treated animals nor the MPAtreated animals differed in COX-2 immunostaining compared with C ( Fig. 4A; Table 1 ). TAM showed decreased COX-2 immunostaining compared with CEE + MPA in the stroma (Fig. 4A; Table 1 ). Combined treatment with CEE + MPA increased stromal COX-2 immunoreactivity compared with no treatment (C) in experiment 2, with a tendency to produce a similar result in experiment 1 (Fig. 4A, B ; Table 1 ). In Table 1 ).
Breast
In the CEE, MPA, TAM, and TIB groups, there was no difference in COX-1 immunostaining compared with controls ( Fig. 5A, B ; Table 2 ). In experiment 1, COX-1 immunoreactivity was decreased in the GE of the CEE + MPA group compared with those of the TAM and MPA groups ( Fig. 5A ; Table 2 ). In addition, in experiment 2, the CEE + MPA group showed the lowest COX-1 immunoreactivity in GE, but the difference with other treatment groups did not reach significance (P = 0.075; Table 2 ). In the ductal epithelium (DE) in experiment 1, COX-1 immunostaining was decreased in the CEE + MPA treatment group compared with the MPA and control groups (Fig. 5B ; Table 2 ). In addition, in experiment 2, the DE of the CEE + MPA group showed the lowest level of COX-1 immunoreactivity, but the staining was not significantly less than those of the other groups (P = 0.067; Table 2 ).
Therefore, COX-1 immunostaining of the breast epithelia seemed to be down-regulated by combined CEE + MPA treatment. There were no differences in stromal COX-1 immunoreactivity between the treatment groups.
COX-2 immunostaining of GE in experiment 2 was increased in the CEE group compared with the control group ( Fig. 5C ; Table 2 ). There was no difference between any of the treatment groups in experiment 1 (data not shown). There were no differences in the COX-2 immunostaining in the DE or stroma between the different treatment groups in either experiment 1 or 2. Thus, only CEE treatment in experiment 2 showed an effect on COX-2 immunoreactivity in the breast.
DISCUSSION
Although COX-2 has been extensively studied in the context of endometrial and breast cancers, 1, 2 little is known about the functions of COX-1 and COX-2 in normal primate uterus and mammary gland.
We found that both COX-1 and COX-2 are expressed in the uterus and breast of surgically postmenopausal monkeys. COX-1 seems to be the dominant COX in the endometrium and myometrium. This is well in agreement with a previous report, in which COX-1 was found to be a resident enzyme that synthesizes endogenous prostaglandins and maintains the basic physiological functions of prostaglandins in the normal nonpregnant porcine uterus. 25 It has also been demonstrated that the expression of COX-1 is dominant in the uterus of normal nonpregnant sheep 26 and mice. 27 We found combined CEE + MPA to decrease COX-1 immunoreactivity in the myometrium, whereas CEE treatment increased COX-1 in endometrial GE. Combined CEE + MPA treatment increased COX-2 immunoreactivity in the endometrial epithelium and stroma, which is in contrast with a previous study that reported no COX-2 immunoreactivity after treatment by HT. 28 Taken together, the combined treatment seems to inhibit COX-1 but stimulate COX-2 expression in the endometrium. As mentioned before, COX-1 is dominant in the uterus, especially in the myometrium. Therefore, it is possible that the decrease in COX-1 level could balance or even overcome the increase in COX-2. Progestogen is known to protect the endometrium from cancer in a combined treatment compared with estrogen-alone therapy. 29 In contrast to the uterus, COX-2 was more prevalent than COX-1 in the mammary gland. There was widespread immunostaining of COX-2 in the monkey's breast epithelium. Women expressing COX-2 in normal tissue also express it in cancer tissue. 30 Despite its high expression in the breast, COX-2 was less regulated than COX-1 by the treatments in our study. Only the single CEE treatment increased COX-2 immunostaining in the breast GE. Results from the Women's Health Initiative trial showed that single CEE use induces a significant increase in mammographic density that is persistent over at least 2 years. 31 In a recent article, COX-2 expression was shown to be higher in dense than in nondense breast. 32 Mammographic density relates to proliferation in local breast tissue and is positively associated with breast cancer risk. 33 TAM is an antiestrogen in the breast, with agonistic effects on the endometrium. 10 Women receiving long-term TAM therapy have an increased risk of developing endometrial cancer. 11 In the present study, TAM treatment had no significant effect on the immunostaining of COX-1 and COX-2 in the uterus and breast compared with controls. A previous study showed that the uterine messenger RNA expression of COX-1 is not affected by TAM treatment, 34 which is in agreement with our results.
In the interest of optimizing the risk/benefit ratio of HT, TIB was developed. After oral administration, it is converted into three major metabolites, two of them estrogenic and one with progestogenic and androgenic properties. The summary effect of the metabolites on the endometrium is a weak estrogenic activity. 19 TIB has low estrogenic effects on the breast because it blocks some of the local enzyme systems, which impair active estrogen formation. 19 Clinically, few women receiving TIB treatment complain of adverse effects on the breast, and breast density is not increased. 19 In our study, TIB increased COX-2 immunostaining in the endometrial GE but showed no effects on the breast.
CONCLUSIONS
Our results show that COX-1 and COX-2 are differently distributed and regulated by hormone treatment in the normal uterus and breast from ovariectomized macaques. COX-1 is more dominant in the uterus and is decreased by combined estrogen and progestogen treatment, whereas COX-2 immunostaining is increased by the same treatment. On the other hand, COX-2 is prevailing in the mammary gland but is less regulated in this tissue than is COX-1, which is decreased by the combined treatment.
